EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Late Adverse Effects after Treatment for Childhood Acute Leukemia

Jelena Roganovic, Riccardo Haupt, Edit Bárdi, Lars Hjorth, Gisela Michel, Vesna Pavasovic, Katrin Scheinemann, Helena Jh van der Pal, Lorna Zadravec Zaletel, Ana E Amariutei, Roderick Skinner, PanCare Board

Acta Medica Academica · 2024

DOI: 10.5644/ama2006-124.438 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Medica Academica, 2024. Verfasst von Jelena Roganovic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology and Oncology, Children's Hospital Zagreb, Zagreb, Croatia; Faculty of Biotechnology and Drug Development, Universi…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Cancer Survivors. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this review is to raise awareness and knowledge among healthcare professionals and policymakers about late adverse effects in survivors of childhood leukemia. With contemporary treatment, over 90% of children with acute lymphoblastic leukemia (ALL) and over 60% with acute myeloid leukemia (AML) are cured. Large cohort studies demonstrate that 20% of ALL and most AML survivors have at least one chronic health condition by 20-25 years after diagnosis. These are life-changing or threatening in some survivors and contribute to increased premature mortality. We describe the frequency, causes, clinical features, and natural history of the most frequent and severe late adverse effects in childhood leukemia survivors, including subsequent malignant neoplasms, metabolic toxicity, gonadotoxicity and impaired fertility, endocrinopathy and growth disturbances, bone toxicity, central and peripheral neurotoxicity, cardiotoxicity, psychosocial late effects, accelerated ageing and late mortality. The wide range of late effects in survivors of haemopoietic stem cell transplant is highlighted. Recent developments informing the approach to long-term survivorship care are discussed, including electronic personalized patient-specific treatment summaries and care plans such as the Survivor Passport (SurPass), surveillance guidelines and models of care. The importance of ongoing vigilance is stressed given the increasing use of novel targeted drugs with limited experience of long-term outcomes. Conclusion. It is vital to raise awareness of the existence and severity of late effects of childhood leukemia therapy among parents, patients, health professionals, and policymakers. Structured long-term surveillance recommendations are necessary to standardize follow-up care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaCancer SurvivorsHumansChildHematopoietic Stem Cell TransplantationLong Term Adverse EffectsAntineoplastic Agents

Stichwörter der Autor:innen

Acute LeukemiaChildLate EffectsLong-Term Follow-UpSurvivor

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Pediatric Hematology and Oncology, Children's Hospital Zagreb, Zagreb, Croatia; Faculty of Biotechnology and Drug Development, University of Rijeka, Rijeka, Croatia.
  • Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genova, Italy.
  • St. Anna Childrens Hospital, Wien; Department of Pediatrics and Adolescent Medicine, Johannes Kepler University Linz, Kepler University Hospital, Linz, Austria.
  • Department of Pediatrics, Skane University Hospital; Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.
  • Department of Paediatric Haematology and Oncology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom.

Zitieren

APA

Roganovic, J., Haupt, R., Bárdi, E., Hjorth, L., Michel, G., Pavasovic, V., Scheinemann, K., van der Pal, H. J., Zadravec Zaletel, L., Amariutei, A. E., Skinner, R., & PanCare Board (2024). Late Adverse Effects after Treatment for Childhood Acute Leukemia. Acta Medica Academica. https://doi.org/10.5644/ama2006-124.438

Vancouver

Roganovic J, Haupt R, Bárdi E, Hjorth L, Michel G, Pavasovic V, et al. Late Adverse Effects after Treatment for Childhood Acute Leukemia. Acta Medica Academica. 2024. doi:10.5644/ama2006-124.438

BibTeX
@article{Roganovic2024,
  author = {Roganovic, Jelena and Haupt, Riccardo and Bárdi, Edit and Hjorth, Lars and Michel, Gisela and Pavasovic, Vesna and Scheinemann, Katrin and van der Pal, Helena Jh and Zadravec Zaletel, Lorna and Amariutei, Ana E and Skinner, Roderick and PanCare Board, PanCare Board},
  title = {Late Adverse Effects after Treatment for Childhood Acute Leukemia},
  journal = {Acta Medica Academica},
  year = {2024},
  doi = {10.5644/ama2006-124.438}
}
Kostenlos starten →